Table of Contents
1 Table of Contents 2
1.1 List of Tables 2
1.2 List of Figures 3
2 Executive Summary 4
2.1 Substantial Unmet Needs Remain in Core Therapy Types 4
2.2 Highly Diversified Range of Innovative Programs in Early Pipeline 4
2.3 Rich Pipeline Landscape with Numerous Investment Opportunities 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Development Remains Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.1.1 Chronic and Neuropathic Pain 10
4.1.2 Disease Pathophysiology 11
4.1.3 Diagnosis 14
4.1.4 Treatment Options 15
4.2 Overview of Marketed Products for Pain 16
4.2.1 Analgesic Product Categories 16
4.2.2 Molecular Type Analysis 18
4.2.3 Current Unmet Needs 18
5 Assessment of Pipeline Product Innovation in Chronic, Acute and Neuropathic Pain 20
5.1 Pain Pipeline by Molecule Type, Stage of Development and Molecular Target 20
5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic Target Family 23
5.3 First-in-Class Pipeline Programs 23
5.4 First-in-Class and Established Pipeline Products by Pain Subtype 26
5.5 Table of All First-in-Class Pain Pipeline Products 30
6 Pain Pathophysiology and Innovation Alignment 32
6.1 The Complexity of Signaling Networks in the Central Nervous System 32
6.2 Matrix Assessment 32
7 First-in-Class Target and Pipeline Program Evaluation 35
7.1 Pipeline Programs Targeting XXX 35
7.2 Pipeline Programs Targeting XXX 37
7.3 Pipeline Programs Targeting XXX 38
7.4 Pipeline Programs Targeting XXX 41
7.5 Pipeline Programs Targeting XXX 43
7.6 Pipeline Programs Targeting XXX 44
7.7 Pipeline Programs Targeting XXX 46
8 Deals and Strategic Consolidations 48
8.1 Industry-Wide First-in-Class Deals 48
8.2 Pain Deals Landscape 49
8.3 Licensing Deals 49
8.3.1 Molecule Type 51
8.3.2 Mechanism of Action 52
8.4 Co-development Deals 54
8.4.1 Molecule Type 55
8.4.2 Mechanism of Action 56
8.5 List of Pipeline Products without Prior Licensing or Co-Development Deal Involvement 58
9 Appendix 60
9.1 Abbreviations 60
9.2 References 60
9.3 Research Methodology 70
9.4 Secondary Research 70
9.4.1 Market Analysis 70
9.4.2 Pipeline Analysis 70
9.4.3 First-in-Class Matrix Assessment 71
9.4.4 First-in-Class Target Profiles 71
9.4.5 Licensing and Co-development Deals 71
9.5 Contact Us 72
9.6 Disclaimer 72